StockData
BioCryst Pharmaceuticals Inc logo

BioCryst Pharmaceuticals Inc (BCRX) stock

BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30
$7.30−0.20 (-2.67%)

Close on Nov 18, 2026Market cap $1.87BP/E –Yield –

BioCryst Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

BioCryst Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $940.61M, up 68.7% year over year. For fiscal 2025 it was $874.84M, up 94.1% from the year before. Over ten years it grew 33.6% a year on average. The highest annual figure on record is $874.84M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$874.84M+94.1%
FY2024Dec 31, 2024$450.71M+36.0%
FY2023Dec 31, 2023$331.41M+22.4%
FY2022Dec 31, 2022$270.83M+72.3%
FY2021Dec 31, 2021$157.17M+782.4%
FY2020Dec 31, 2020$17.81M-63.5%
FY2019Dec 31, 2019$48.84M+136.5%
FY2018Dec 31, 2018$20.65M-18.0%
FY2017Dec 31, 2017$25.19M-4.4%
FY2016Dec 31, 2016$26.35M-45.4%
FY2015Dec 31, 2015$48.26M+254.6%
FY2014Dec 31, 2014$13.61M-21.5%
FY2013Dec 31, 2013$17.33M-34.1%
FY2012Dec 31, 2012$26.29M+33.9%
FY2011Dec 31, 2011$19.64M-68.5%
FY2010Dec 31, 2010$62.38M-16.4%
FY2009Dec 31, 2009$74.59M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$218.25M+33.6%
Q1 FY2026Mar 31, 2026$156.41M+7.5%
Q4 FY2025Dec 31, 2025$406.56M+209.1%
Q3 FY2025Sep 30, 2025$159.40M+36.1%
Q2 FY2025Jun 30, 2025$163.35M+49.4%
Q1 FY2025Mar 31, 2025$145.53M+56.9%
Q4 FY2024Dec 31, 2024$131.53M+40.8%
Q3 FY2024Sep 30, 2024$117.09M+35.0%
Q2 FY2024Jun 30, 2024$109.33M+32.5%
Q1 FY2024Mar 31, 2024$92.76M+34.9%
Q4 FY2023Dec 31, 2023$93.40M+17.4%
Q3 FY2023Sep 30, 2023$86.74M+14.4%
Q2 FY2023Jun 30, 2023$82.49M+25.9%
Q1 FY2023Mar 31, 2023$68.78M+37.8%
Q4 FY2022Dec 31, 2022$79.55M+68.7%
Q3 FY2022Sep 30, 2022$75.83M+85.0%
Q2 FY2022Jun 30, 2022$65.53M+31.2%
Q1 FY2022Mar 31, 2022$49.92M+161.9%
Q4 FY2021Dec 31, 2021$47.16M+1074.3%
Q3 FY2021Sep 30, 2021$40.99M+571.8%
Q2 FY2021Jun 30, 2021$49.96M+1640.1%
Q1 FY2021Mar 31, 2021$19.06M+295.2%
Q4 FY2020Dec 31, 2020$4.02M-89.9%
Q3 FY2020Sep 30, 2020$6.10M+243.8%
Q2 FY2020Jun 30, 2020$2.87M+98.3%
Q1 FY2020Mar 31, 2020$4.82M-18.1%
Q4 FY2019Dec 31, 2019$39.73M+1355.7%
Q3 FY2019Sep 30, 2019$1.78M+22.1%
Q2 FY2019Jun 30, 2019$1.45M-88.4%
Q1 FY2019Mar 31, 2019$5.89M+48.1%
Q4 FY2018Dec 31, 2018$2.73M-29.8%
Q3 FY2018Sep 30, 2018$1.45M-83.4%
Q2 FY2018Jun 30, 2018$12.49M+303.2%
Q1 FY2018Mar 31, 2018$3.98M-57.9%
Q4 FY2017Dec 31, 2017$3.89M-56.7%
Q3 FY2017Sep 30, 2017$8.76M+12.8%
Q2 FY2017Jun 30, 2017$3.10M–
Q1 FY2017Mar 31, 2017$9.44M–
Q4 FY2016Dec 31, 2016$8.98M–
Q3 FY2016Sep 30, 2016$7.76M–

More BioCryst Pharmaceuticals figures

See a number that looks wrong?